Think Research Corporation Stock

Equities

THNK

CA88410J1075

Software

Delayed Toronto S.E. 11:10:54 2024-04-22 am EDT 5-day change 1st Jan Change
0.315 CAD 0.00% Intraday chart for Think Research Corporation +1.61% +65.79%
Sales 2023 * 84.14M 61.53M Sales 2024 * 91.36M 66.81M Capitalization 24.95M 18.25M
Net income 2023 * -14M -10.24M Net income 2024 * -15M -10.97M EV / Sales 2023 * 0.83 x
Net Debt 2023 * 44.92M 32.85M Net Debt 2024 * 55.75M 40.77M EV / Sales 2024 * 0.88 x
P/E ratio 2023 *
-1.66 x
P/E ratio 2024 *
-1.66 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.72%
More Fundamentals * Assessed data
Dynamic Chart
Beedie Capital completed the acquisition of remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders. CI
Transcript : Think Research Corporation - Shareholder/Analyst Call
Think Research Says No Alternative Buyers Emerge as Shareholder Vote Next Week on Going Private Transaction MT
Think Research Brief: Co Says "Now subject to a non-solicitation covenant with customary "fiduciary out" provisions Under Terms of the Arrangement Agreement MT
Think Research Brief: Providing Update on Going Private Transaction; "Go-shop" Period Expired on March 16, 2024, With No Acquisition Proposal Having Been Received MT
Think Research Corp. Provided a Financial Update MT
Think Research Announces $5.0 Million Contract Expansion with a Global Pharmaceutical Company CI
Think Research Agrees to be Bought by Beedie Capital; Up 87.5% MT
Think Research Agrees to be Bought by Beedie Capital MT
Think Research Brief: Shareholders to receive cash payment of $0.32 per Common Share MT
Think Research Brief: Entering into Definitive Agreement to be Acquired by Beedie Capital MT
Beedie Capital entered into an arrangement agreement to acquire remaining stake in Think Research Corporation (TSXV : THNK) from shareholders. CI
Think Research Secures $1 Million Subsequent Advance Under Existing Convertible Facility; Up 7% MT
Think Research Secures $1 Million Subsequent Advance Under Existing Convertible Facility MT
Think Research's Learning Management System to Support Healthcare Professional Education and Training CI
More news

Latest transcript on Think Research Corporation

1 week+1.61%
Current month+1.61%
1 month+1.61%
3 months+80.00%
6 months+12.50%
Current year+65.79%
More quotes
1 week
0.32
Extreme 0.315
0.32
1 month
0.30
Extreme 0.3
0.32
Current year
0.16
Extreme 0.16
0.32
1 year
0.15
Extreme 0.15
0.43
3 years
0.15
Extreme 0.15
4.20
5 years
0.15
Extreme 0.15
5.75
10 years
0.15
Extreme 0.15
5.75
More quotes
Managers TitleAgeSince
Chief Executive Officer - 09-12-31
Director of Finance/CFO - 22-04-14
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 75 -
Director/Board Member - -
Director/Board Member 57 -
More insiders
Date Price Change Volume
24-04-22 0.315 0.00% 15,057
24-04-19 0.315 +1.61% 23,000
24-04-18 0.31 0.00% 406,000
24-04-16 0.31 0.00% 1,499,415

Delayed Quote Toronto S.E., April 22, 2024 at 11:10 am EDT

More quotes
Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings